EGFR and pneumonitis: A retrospective analysis by Schoenfeld et al. suggested an increased risk of pneumonitis (e.g., 9.7% incidence of grade 3 pneumonitis) with the use of osimertinib sequentially following a PD-(L)1 immune checkpoint inhibitor; interestingly, this risk of pneumonitis was specific to osimertinib and not observed with other EGFR TKIs (e.g., the first-generation TKI erlotinib or second-generation TKI afatinib) [125].